All Featured Insights

Congress scrambles for a new funding deal, a report details the financial impacts of a mandatory bundled payment model, and a woman receives a genetically modified pig kidney transplant.

Congress scrambles for a new funding deal, a report details the financial impacts of a mandatory bundled payment model, and a woman receives a genetically modified pig kidney transplant.

Supplemental funding programs, cybersecurity risks, and industry outlooks were the themes of this year’s Therese L. Wareham Rating Agency Panel at the 2024 Kaufman Hall Healthcare Leadership Conference.

On today’s episode, host J. Carlisle Larsen speaks with POLITICO’s Ben Leonard to talk more about his healthcare choices, their chances of getting confirmed by the Senate, and what his picks could signal about his second administration’s priorities.

It has been an incredibly busy and exciting year for our Strategy & Business Transformation practice at Kaufman Hall. In 2024, we observed hospitals and health systems take steps to reinvigorate their strategic efforts amid a stabilizing, but still challenging, outlook.

With the onset of the pandemic in March 2020, states were required to provide continuous enrollment for Medicaid and Children’s Health Insurance Program (CHIP) beneficiaries in exchange for enhanced federal funding.

Congress negotiates its year-end healthcare package, Dreamers lose access to ACA exchanges, and Elevance reverses its controversial anesthesia policy.

The future will favor payers that adapt to changing market circumstances with agency and velocity. Payers will need to make tough choices.

With extension of the 2017 tax cuts identified as a key priority for the incoming Trump administration, offsetting expense actions will be needed to avoid increasing the federal deficit. Hospital leaders should be prepared for potential cuts to both the Medicaid program and the enhanced ACA subsidies enacted in 2021.

As hospitals and health systems intensify their financial planning efforts, revisiting and refining the forecasting techniques and tools that guide their decisions has become paramount.

Carol Skenes, Interim Vice President of Product at Turquoise, joins host J. Carlisle Larsen to talk about what their researchers found after reviewing industry-wide data.

This month’s data show general stability, with continued growth in outpatient revenue and expense reductions on a volume-adjusted basis.